Search

Your search keyword '"Uchida, Yujiro"' showing total 27 results
Start Over Author "Uchida, Yujiro"
27 results on '"Uchida, Yujiro"'

1. Efficacy and Safety of Favipiravir in Moderate COVID-19 Pneumonia Patients without Oxygen Therapy: A Randomized, Phase III Clinical Trial

Author

Shinkai, Masaharu, Tsushima, Kenji, Tanaka, Shingo, Hagiwara, Eri, Tarumoto, Norihito, Kawada, Ichiro, Hirai, Yuji, Fujiwara, Sho, Komase, Yuko, Saraya, Takeshi, Koh, Hidefumi, Kagiyama, Naho, Shimada, Megumi, Kanou, Daiki, Antoku, Shinichi, Uchida, Yujiro, Tokue, Yutaka, Takamori, Mikio, Gon, Yasuhiro, Ie, Kenya, Yamazaki, Yoshitaka, Harada, Kazumasa, Miyao, Naoki, Naka, Takashi, Iwata, Mitsunaga, Nakagawa, Atsushi, Hiyama, Kazutoshi, Ogawa, Yoshihiko, Shinoda, Masahiro, Ota, Shinichiro, Hirouchi, Takatomo, Terada, Jiro, Kawano, Shuichi, Ogura, Takashi, Sakurai, Tsutomu, Matsumoto, Yoshihiko, Kunishima, Hiroyuki, Kobayashi, Osamu, and Iwata, Satoshi

Published
2021
Full Text
View/download PDF

12. A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19

Author

Doi, Yohei, primary, Hibino, Masaya, additional, Hase, Ryota, additional, Yamamoto, Michiko, additional, Kasamatsu, Yu, additional, Hirose, Masahiro, additional, Mutoh, Yoshikazu, additional, Homma, Yoshito, additional, Terada, Masaki, additional, Ogawa, Taku, additional, Kashizaki, Fumihiro, additional, Yokoyama, Toshihiko, additional, Koba, Hayato, additional, Kasahara, Hideki, additional, Yokota, Kazuhisa, additional, Kato, Hideaki, additional, Yoshida, Junichi, additional, Kita, Toshiyuki, additional, Kato, Yasuyuki, additional, Kamio, Tadashi, additional, Kodama, Nobuhiro, additional, Uchida, Yujiro, additional, Ikeda, Nobuhiro, additional, Shinoda, Masahiro, additional, Nakagawa, Atsushi, additional, Nakatsumi, Hiroki, additional, Horiguchi, Tomoya, additional, Iwata, Mitsunaga, additional, Matsuyama, Akifumi, additional, Banno, Sumi, additional, Koseki, Takenao, additional, Teramachi, Mayumi, additional, Miyata, Masami, additional, Tajima, Shigeru, additional, Maeki, Takahiro, additional, Nakayama, Eri, additional, Taniguchi, Satoshi, additional, Lim, Chang Kweng, additional, Saijo, Masayuki, additional, Imai, Takumi, additional, Yoshida, Hisako, additional, Kabata, Daijiro, additional, Shintani, Ayumi, additional, Yuzawa, Yukio, additional, and Kondo, Masashi, additional

Published
2020
Full Text
View/download PDF

21. Japanese Journal of Environmental Infections

Author

MIYAKE, Noriko, primary, SHIMONO, Nobuyuki, additional, MAEHARA, Yoriko, additional, GONDO, Tae, additional, NAGASAKI, Yoji, additional, UCHIDA, Yujiro, additional, MURATA, Masayuki, additional, and HAYASHI, Jun, additional

Published
2009
Full Text
View/download PDF

23. Japanese Journal of Environmental Infections

Author

MAEHARA, Yoriko, primary, SHIMONO, Nobuyuki, additional, UCHIDA, Yujiro, additional, OGAWA, Eiichi, additional, OTAGURO, Sigeru, additional, KANAMOTO, Yoko, additional, MURATA, Masayuki, additional, MATSUMOTO, Hiroko, additional, GONDO, Tae, additional, and HAYASHI, Jun, additional

Published
2008
Full Text
View/download PDF

26. [Influence of inoculum size on MICs for methicillin-susceptible Staphylococcus aureus and methicillin-resistant Staphylococcus aureus].

Author

Miyake N, Kadowaki M, Sato Y, Eriguchi Y, Nagasaki Y, Harada Y, Uchida Y, and Shimono N

Subjects
Dibekacin pharmacology, Drug Resistance, Bacterial, Linezolid, Meropenem, Acetamides pharmacology, Ampicillin pharmacology, Anti-Bacterial Agents pharmacology, Anti-Infective Agents pharmacology, Bacteriological Techniques methods, Cefazolin pharmacology, Ciprofloxacin pharmacology, Dibekacin analogs & derivatives, Methicillin-Resistant Staphylococcus aureus drug effects, Microbial Sensitivity Tests methods, Oxazolidinones pharmacology, Staphylococcus aureus drug effects, Teicoplanin pharmacology, Thienamycins pharmacology, Vancomycin pharmacology
Abstract

Using 49 clinical methicillin-susceptible Staphylococcus aureus isolates (MSSA) and 54 clinical methicillin-resistant Staphylococcus aureus (MRSA) isolates, we examined the change of MIC using five different inocula (2.5-4 x 10(2) cfu/spot-2.5-4 x 10(6) cfu/spot). We found the big change of the MIC with the increase of the inoculum size in ampicillin against MSSA, and the change was small in cefazolin, meropenem, ciprofloxacin. For anti-MRSA antibiotics, we found the small change with the increase of the inoculums size in vancomycin and arbekacin, and the middle change in teicoplanin and linezolid against MSSA and MRSA. The data from this study suggest that in serious and high inocula infections caused by S. aureus, the presence of an inoculum effect should be considered in curing.

Published
2011

27. [Microbiological and clinical features of nine cases with nocardial infections].

Author

Maki Y, Uchida Y, Monji N, Mochimaru T, Morokuma Y, Karashima T, Kiyosuke M, Fujise M, Eto F, Miyake N, Shimono N, Kayamori Y, and Kang D

Subjects
Adult, Aged, Aged, 80 and over, Anti-Bacterial Agents pharmacology, Collagen Diseases complications, Drug Resistance, Bacterial, Female, Humans, Immunocompromised Host, Immunologic Deficiency Syndromes complications, Lung Diseases complications, Male, Microbial Sensitivity Tests, Middle Aged, Neoplasms complications, Nocardia classification, Nocardia genetics, Nocardia Infections complications, Opportunistic Infections complications, RNA, Bacterial, RNA, Ribosomal, 16S, Nocardia drug effects, Nocardia isolation & purification, Nocardia Infections microbiology
Abstract

Following recent advance in medical technology, the increase of immunocompromised patients results in an increase of opportunistic infections such as nocardiosis. However, little is known about relationships between clinical features of nocardial infections and each Nocardia species, especially newly identified ones. Therefore, we identified clinical isolates of Nocardia species by genetic methods and analyzed clinical features of nocardiosis. Nine clinical isolates were obtained in Kyushu University Hospital from 2005 to 2008. Six different Nocardia species were identified by 16Sr RNA: Nocardiafarcinia (n=2), Nocardia brasiliensis (n=2), Nocardia cyriacigeorgica (n=2), Nocardia transvalensis (n=1), Nocardia araoensis (n=1) and Nocardia testacea (n=1). The underlying diseases of 9 patients were pulmonary diseases(n=5), malignant diseases(n=3), collagen diseases(n=1) or primary immunodeficiency diseases (n=l). According to antimicrobial susceptibility testing, none of them was resistant to minocycline or linezolid. Among seven isolates from respiratory specimens, one was resistant to imipenem, sulfamethoxazole/trimethoprim and amikacin, two were to ciprofloxacin. Three species identified recently (N cyriacigeorgica, N. araoensis and N. testacea) were involved in this study and most of them were considered as infectious pathogens to human. These data suggested the identification of Nocardia to the species level and susceptibility testing were important for diagnosis as infectious diseases and treatments.

Published
2011

Catalog

Books, media, physical & digital resources
See catalog results